RT-treated patients with low ARID1A expression from other tumor entities, such as skin cutaneous melanoma (SKCM), thyroid carcinoma (THCA), and glioblastoma multiforme (GBM), displayed higher expression of CXCL10, IL-6 and CXCL9. The gene discussed is ARID1A; the disease is thyroid gland carcinoma.